INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NK’s Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy
Completion of Phase 1 First-in-Human Trials of Cryopreserved, Off-The-Shelf haNK Cells Leads the Way to Pivotal Phase 2 Trials in Relapsed Merkel Cell Carcinoma Funding to Support INDs for First-in-Human Targeted Off-The-Shelf NK Cells (t-haNKs) with PD-L1 and CD-19 as Tumor Targets CULVER CITY,
View HTML
Toggle Summary NantKwest Builds Financial and Commercial Expertise with the Appointment of Fred Driscoll to Its Board of Directors
CULVER CITY, Calif. --(BUSINESS WIRE)--Sep. 22, 2017-- NantKwest, Inc. (Nasdaq:NK) today announced that Fred Driscoll , currently an Advisor and former Chief Financial Officer of Flexion Therapeutics, Inc. , has been appointed to the Board to fill the position being vacated by Mr.
View HTML
Toggle Summary NantKwest Augments, Strengthens Senior Management Team
-- Company Adds Clinical Development , Medical Affairs and M&A Executives -- CULVER CITY, Calif. --(BUSINESS WIRE)--Sep. 22, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to
View HTML
Toggle Summary NantKwest Appoints Dr. Leonard Sender as Senior Vice President of Medical Affairs for Pediatric, Adolescent and Young Adult Oncology
Company adds esteemed pediatric, adolescent and young adult oncology expert to leadership team CULVER CITY, Calif. --(BUSINESS WIRE)--May 16, 2017-- NantKwest Inc . (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune
View HTML
Toggle Summary NantKwest Appoints Dr. John Lee as Senior Vice President of Adult Medical Affairs
Company Adds Immuno-Oncology and Clinical Trial Expert to Leadership Team CULVER CITY, Calif. --(BUSINESS WIRE)--May 18, 2017-- NantKwest Inc.  (NASDAQ:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural
View HTML
Toggle Summary NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta Therapeutics
Phase Ib/II Clinical Trial Data Reported at 2019 Annual Meeting of the American Society of Clinical Oncology Shows High Overall Objective Response Rate (ORR) of 58% and Complete Response Rate (CR) of 33% in Relapsed/Refractory Lymphoma Patients CULVER CITY, Calif. --(BUSINESS WIRE)--Jun.
View HTML
Toggle Summary NantKwest Announces Successful First in Human Administration of CD16 High Affinity Natural Killer (haNK) Cells
Successful Administration Of Off The Shelf Hank Cells In Patients With Solid Tumors Paves The Way To Nation's First Combination Innate And Adaptive NANT Cancer Vaccine Trials In Multiple Tumor Types CULVER CITY, Calif. --(BUSINESS WIRE)--Oct. 2, 2017-- NantKwest Inc.
View HTML
Toggle Summary NantKwest Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab Providing Strong Rationale for Advancement to Human Clinical Trials
CULVER CITY, Calif. --(BUSINESS WIRE)--Jul. 25, 2017-- NantKwest Inc. (Nasdaq:NK), a clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases, and inflammatory diseases, today announced a
View HTML
Toggle Summary NantKwest Announces Prostate Cancer Foundation $1 Million Challenge Award to Study a Novel Natural Killer Cell Therapy in Prostate Cancer
LOS ANGELES --(BUSINESS WIRE)--Aug. 26, 2015-- NantKwest (Nasdaq:NK), working with Ganesh Palapattu, MD and his team at the University of Michigan , along with Karen Knudsen , PhD and her group at Thomas Jefferson University , announced a $1 Million Challenge award from the Prostate Cancer
View HTML
Toggle Summary NantKwest Announces Promising First in Human Clinical Results of 300 Doses Of CD16 Targeted, Off-The-Shelf Cryopreserved Natural Killer Cells (haNK) in a Novel Cancer Memory Vaccine Immunotherapy
Combination in 30 Patients with Advanced Metastatic Cancer Refractory to Multiple Previous Therapies Zero Incidence of Cytokine Release Syndrome in Any of the 300 Doses in 30 Patients All Patients Received NK Cell Infusion and Novel Cancer Memory Vaccine Combination as Outpatients with No
View HTML